Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all

Por Maughan, Benjamin L, Antonarakis, Emmanuel S
Publicado no Asian J Androl (2014)

Androgen pathway resistance in prostate cancer and therapeutic implications

Por Maughan, Benjamin L, Antonarakis, Emmanuel S
Publicado no Expert Opin Pharmacother (2015)

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers

Por Maughan, Benjamin L., Bailey, Erin, Gill, David M., Agarwal, Neeraj
Publicado no Front Oncol (2017)

Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer

Por Patel, Jesal C., Maughan, Benjamin L., Agarwal, Archana M., Batten, Julia A., Zhang, Tian Y., Agarwal, Neeraj
Publicado em 2013

Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma

Por Agarwal, Neeraj, Bellmunt, Joaquim, Maughan, Benjamin L., Boucher, Kenneth M., Choueiri, Toni K., Qu, Angela Q., Vogelzang, Nicholas J., Fougeray, Ronan, Niegisch, Guenter, Albers, Peter, Wong, Yu-Ning, Ko, Yoo-Joung, Sridhar, Srikala S., Tantravahi, Srinivas K., Galsky, Matthew D., Petrylak, Daniel P., Vaishampayan, Ulka N., Mehta, Amitkumar N., Beer, Tomasz M., Sternberg, Cora. N., Rosenberg, Jonathan E., Sonpavde, Guru
Publicado em 2013